Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Early [¹⁸F]fluorodeoxyglucose positron emission tomography-based response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: a children's oncology group report. Pediatr Hematol Oncol 2010 Nov;27(8):650-7

Date

09/25/2010

Pubmed ID

20863157

Pubmed Central ID

PMC3083978

DOI

10.3109/08880018.2010.504250

Scopus ID

2-s2.0-77958051538   1 Citation

Abstract

The International Harmonization Project defined complete response (CR) after treatment for Hodgkin disease (HD) by absence of fluorodeoxyglucose avidity, regardless of the size of residual masses. Residual avidity after initial treatment is known to predict inferior survival. In the setting of retrieval therapy, early positron emission tomography (PET) scans may improve assessment of treatment efficacy. Retrospective analysis after 2 cycles of gemcitabine and vinorelbine for refractory HD revealed 6 CR among 13 patients by PET and 1 CR in 13 by computed tomography (CT). No relationship between PET response and event-free or overall survival could be discerned, presumably because of the heterogeneity of subsequent therapies.

Author List

Cole PD, McCarten KM, Drachtman RA, Alarcon Pd, Chen L, Trippett TM, Schwartz CL

Author

Cindy L. Schwartz MD, MPH Chief, Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Antineoplastic Combined Chemotherapy Protocols
Deoxycytidine
Fluorodeoxyglucose F18
Hodgkin Disease
Humans
Positron-Emission Tomography
Recurrence
Research Report
Retrospective Studies
Survival Analysis
Vinblastine
jenkins-FCD Prod-461 7d7c6113fc1a2757d2947d29fae5861c878125ab